Silo Pharma (NASDAQ: SILO) is highlighting progress in its post‑traumatic stress disorder (PTSD) program as U.S. regulators move faster on psychedelic‑based mental health treatments. A recent…
April 29, 2026
Silo Pharma (NASDAQ: SILO) is highlighting progress in its post‑traumatic stress disorder (PTSD) program as U.S. regulators move faster on psychedelic‑based mental health treatments. A recent…